TOI Form 4 shows director stock awards and 268,302 shares owned

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI) director reports new stock awards. A board member filed a Form 4 disclosing two grants of common stock in the form of restricted stock units on 11/20/2025. One award covers 50,926 restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, assuming continued service. The second award covers 40,123 restricted stock units that were fully vested upon grant. Both awards are shown at a price of $0 per share, reflecting that they are equity compensation rather than open-market purchases. After these grants, the director beneficially owns 268,302 shares of common stock in direct ownership.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Kaushal Mohit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	50,926	$0.00	--
Grant/Award	Common Stock	40,123	$0.00	--

Holdings After Transaction: Common Stock — 228,179 shares (Direct)

Footnotes (1)

1. Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date. Represents restricted stock units that were fully vested upon grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaushal Mohit

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		A		50,926(1)	A	$0	228,179	D
Common Stock	11/20/2025		A		40,123(2)	A	$0	268,302	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest in full on Issuer's 2026 annual stockholder meeting date, subject to continued service with the Issuer through such vesting date.

2. Represents restricted stock units that were fully vested upon grant.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mohit Kaushal	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the TOI director report on this Form 4?

The Form 4 reports that a director of Oncology Institute, Inc. (TOI) received two restricted stock unit awards of the company’s common stock on 11/20/2025.

How many TOI restricted stock units were granted to the director?

The director received 50,926 restricted stock units that vest at the 2026 annual stockholder meeting and 40,123 restricted stock units that were fully vested upon grant.

At what price were the TOI stock awards reported?

Both restricted stock unit awards are reported at a price of $0 per share, indicating they are equity compensation grants rather than market purchases.

When do the TOI restricted stock units vest?

The 50,926 restricted stock units vest in full on TOI’s 2026 annual stockholder meeting date, subject to continued service. The 40,123 units were fully vested upon grant.

How many TOI shares does the director own after these transactions?

Following the reported transactions, the director beneficially owns 268,302 shares of TOI common stock in direct ownership.

What is the director’s relationship to Oncology Institute, Inc.?

The reporting person is identified as a director of Oncology Institute, Inc. (TOI) and filed the Form 4 as an individual reporting person.